PMID: 8954140Oct 1, 1996Paper

Anti-idiotype cancer vaccines: past and future

Cancer Immunology, Immunotherapy : CII
D HerlynH Maruyama

Abstract

Anti-idiotypic antibodies (Ab2) binding to the antigen-combining site of antitumor antibodies (Ab1) can induce anti-anti-idiotypic antibodies (Ab3) that specifically bind to the tumor antigen recognized by Ab1. Furthermore, Ab2, mimicking tumor antigens, have been shown to induce anti-anti-idiotypic proliferative T lymphocytes of the helper and suppressor type, as well as cytotoxic lymphocytes. The immunomodulatory activities of Ab2 have been demonstrated both in animals and in patients. The demonstration of tumor growth inhibition by anti-idiotypes in preclinical and phase I clinical studies emphasizes that randomized control trials should be performed to demonstrate clinical efficacy of Ab2 vaccines.

Citations

Apr 4, 2003·Critical Reviews in Oncology/hematology·Piero DalerbaGiorgio Parmiani
Feb 12, 1998·American Journal of Reproductive Immunology : AJRI·C A Mullen
Mar 7, 2000·Clinical and Diagnostic Laboratory Immunology·A R SouzaJ D Lopes
Oct 31, 2002·Seminars in Oncology·Jose LutzkyJennifer A Orzano
Oct 31, 2002·Seminars in Oncology·Maresa Altomonte, Michele Maio
Sep 9, 2016·Immunotherapy·Lucia SignoriniMarco Bregni
Apr 30, 2019·Frontiers in Immunology·Heinz KohlerThomas Kieber-Emmons
Oct 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ana María HernándezRolando Pérez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.